Janiczek Wealth Management LLC Sells 331 Shares of Centene Co. (NYSE:CNC)

Janiczek Wealth Management LLC trimmed its holdings in Centene Co. (NYSE:CNC) by 41.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 466 shares of the company’s stock after selling 331 shares during the quarter. Janiczek Wealth Management LLC’s holdings in Centene were worth $35,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Operose Advisors LLC bought a new position in shares of Centene during the 3rd quarter valued at approximately $25,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Centene during the 4th quarter valued at approximately $25,000. Coppell Advisory Solutions Corp. bought a new position in shares of Centene during the 4th quarter valued at approximately $25,000. ST Germain D J Co. Inc. bought a new position in shares of Centene during the 2nd quarter valued at approximately $26,000. Finally, OFI Invest Asset Management bought a new position in shares of Centene during the 3rd quarter valued at approximately $26,000. 93.63% of the stock is currently owned by institutional investors.

Centene Stock Performance

CNC stock opened at $70.73 on Friday. The firm has a market cap of $37.83 billion, a price-to-earnings ratio of 14.41, a PEG ratio of 0.89 and a beta of 0.38. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.68. Centene Co. has a twelve month low of $60.83 and a twelve month high of $81.42. The business’s fifty day simple moving average is $76.80 and its two-hundred day simple moving average is $74.47.

Centene (NYSE:CNC) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. The firm had revenue of $39.46 billion for the quarter, compared to analyst estimates of $36.16 billion. Centene had a return on equity of 14.26% and a net margin of 1.75%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.86 earnings per share. Analysts predict that Centene Co. will post 6.75 earnings per share for the current year.

Insider Activity

In related news, President Kenneth J. Fasola sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $75.07, for a total transaction of $900,840.00. Following the sale, the president now owns 235,365 shares of the company’s stock, valued at $17,668,850.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Centene news, Director Lori Jean Robinson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $77.41, for a total value of $774,100.00. Following the completion of the sale, the director now owns 11,455 shares of the company’s stock, valued at $886,731.55. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Kenneth J. Fasola sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $75.07, for a total value of $900,840.00. Following the completion of the sale, the president now directly owns 235,365 shares of the company’s stock, valued at approximately $17,668,850.55. The disclosure for this sale can be found here. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. UBS Group increased their target price on Centene from $72.00 to $79.00 and gave the company a “neutral” rating in a research report on Thursday, December 21st. StockNews.com lowered Centene from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 28th. Barclays initiated coverage on Centene in a report on Wednesday, March 6th. They set an “overweight” rating and a $101.00 price target on the stock. Stephens restated an “equal weight” rating and set a $85.00 price target (down previously from $92.00) on shares of Centene in a report on Thursday, March 21st. Finally, Wells Fargo & Company decreased their price target on Centene from $94.00 to $89.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Centene has an average rating of “Moderate Buy” and a consensus target price of $85.08.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.